Brief: Oryzon Says FDA Supports Initiation Of Phase III Trial For Vafidemstat In Borderline Personality Disorder

ORYZON Genomics SA

01/10/2024 06:52

Oct 1 (Reuters) - Oryzon Genomics SA  ORY.MC :
    * RECEIVES MEETING MINUTES FROM END-OF-PHASE II MEETING WITH FDA FOR VAFIDEMSTAT IN
BORDERLINE
PERSONALITY DISORDER (BPD)
    * FDA’S FEEDBACK SUPPORTS THE INITIATION OF THE PHASE III TRIAL
    * AGITATION-AGGRESSION IN BORDERLINE PERSONALITY DISORDER ACKNOWLEDGED AS A POSSIBLE
THERAPEUTIC
INDICATION
    * MAY USE STAXI-2 TRAIT ANGER AS PRIMARY EFFICACY ENDPOINT FOR PORTICO-2
    * CURRENTLY NO FDA-APPROVED TREATMENTS FOR BPD

Source text for Eikon:  ID:nCNMcg5lTh 
Further company coverage:  ORY.MC 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))